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Chronic pain secondary to injury and infl  am-
mation is a prevalent, persistent, and debilitat-
ing problem. Although early work dissected 
the role of sensitization of peripheral nerves in 
painful conditions, it is now appreciated that 
facilitation of spinal processing is also a criti-
cal component in states of infl  ammatory pain. 
Work with these systems has revealed an im-
portant role for spinal nonneuronal cells, such 
as astrocytes and microglia, in the regulation 
of nociception (for review see reference 1). In 
addition, it has been widely emphasized that 
peripheral injury leads to rapid expression and 
release of proinfl  ammatory factors (e.g., TNF-α, 
IL-1β, and prostaglandins [PGs]) at the in-
jury site, which reduce the threshold for ac-
tivation and increase the responsiveness of 
peri  pheral nociceptor terminals. There is in-
creasing evidence that there is a comparable 
  release of such mediators in the spinal dor-
sal horn where these factors mediate facilita-
tion of pain processing, further amplifying the 
nociceptive signaling conveyed to the brain 
(for review see reference 1). Hence, many 
factors that are involved in the initiation of 
  infl  ammation at the peripheral site also drive 
spinal sensitization.
Insights from recent work point to the for-
mation of antiinfl  ammatory lipid mediators in 
response to infl  ammation (for review see refer-
ence 2). In this regard, lipoxins represent a 
unique class of lipid mediators that can func-
tion as “braking signals” in infl   ammation. 
  Lipoxin A4 (LXA4) and LXB4 are positional 
isomers generated from arachidonic acid via 
the phospholipase A2–lipoxygenase pathway 
during cell–cell interactions. LXA4 binds with 
high affi   nity to a G protein–coupled receptor 
termed LXA4 receptor (ALXR) (3–6), also 
known as FPRL1 and FPR2. Activation of 
ALXR stops recruitment of neutrophils and fa-
cilitates resolution of infl  ammation by stimulat-
ing monocytes and macrophages to perform 
phagocytosis without releasing cytokines or 
chemokines. LXA4 also attenuates NF-κB acti-
vation and blocks phosphorylation of p38 and 
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extracellular signal-regulated kinase (ERK; for review see 
reference 2).
It is noteworthy that many of the factors that are attenu-
ated by the lipoxin–ALXR interaction are involved in pain 
processing, both at the site of injury and in the spinal cord. 
Another intriguing link between lipoxins and pain is the ac-
tion of aspirin, which, through acetylation of cyclooxygenase-2, 
redirects the activity of cyclooxygenase-2 from generating 
intermediates of PGs and thromboxane from arachidonic 
acid to generating intermediates of a series of aspirin-trig-
gered lipoxins (ATLs). ATLs display the same antiinfl  amma-
tory activities as the native lipoxins but are more resistant to 
metabolic inactivation (for review see reference 2). It is thus 
possible that the analgesic action of aspirin involves not only 
the inhibition of PG generation but also the formation 
of   antiinfl  ammatory lipoxin analogues. We reasoned that 
  processing of pain signals at the site of infl  ammation, but 
more importantly at the spinal level, is regulated by factors 
such as lipoxins that have resolving and antiinfl  ammatory 
endogenous actions in peripheral tissues, and we accordingly 
performed a series of studies focused on the role of lipoxins 
in infl  ammatory pain.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
Painful infl  ammatory conditions are associated with sensitiza-
tion of specialized sensory neurons that compose the noci-
ceptive (pain) pathway, leading to enhanced pain sensations 
in response to both noxious and nonnoxious stimuli (termed 
hyperalgesia and allodynia, respectively). Lipoxins have anti-
infl  ammatory actions in vivo when administered to the site of 
infl  ammation or systemically by the i.v. or oral route (for re-
view see reference 2). To investigate whether lipoxins block 
pain associated with infl  ammation,  LXA4, LXB4, and the 
more stable ATL analogue (ATLa) and an analogue of LXB4, 
(8,9)-acetylenic LXB4 (8,9-aLXB4), were administered i.v. to 
rats 2 min before injection of carrageenan to the hind paw. 
Figure 1.  Intravenous administration of lipoxins reduces infl  am-
mation-evoked hyperalgesia and edema. Paw withdrawal latency 
(PWL) is plotted versus time for the ipsilateral (ip; injected) and contra-
lateral (c; uninjected) hind paw showing that i.v. injection of LXA4, ATLa 
(A and C), and aLXB4 (B and C), but not 8,9-aLXB4 (B and C), before injec-
tion of carrageenan reduces thermal hyperalgesia. HI (C) is calculated for 
0–4 h. Paw thickness (D) was measured by calipers at different time 
points after induction of infl  ammation. Each time point and bar repre-
sents the mean ± SEM (n = 4–6). *, P < 0.05 as compared with vehicle 
(ip) measurements.JEM VOL. 204, February 19, 2007  247
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Hyperalgesia was assessed by measuring the response latency 
to a thermal stimulus. Typically, intraplantar injection of car-
rageenan results in a transient infl  ammation, apparent as an 
increase in paw volume and reddening of the skin, and hy-
peralgesia with an onset at 2 h that is resolved after 24 h 
(7, 8). Intravenous injection of 10 μg/kg LXA4 (28 nmol/kg), 
10  μg/kg ATLa (24 nmol/kg) and 10 μg/kg LXB4 
(28 nmol/kg), but not 10 μg/kg 8,9-aLXB4 (29 nmol/kg), 
had antihyperalgesic eff  ects (Fig. 1, A and B). The withdrawal 
latencies were signifi  cantly longer for the infl  amed paw in the 
LXA4-, ATLa-, and LXB4-injected animals, as compared with 
the vehicle-treated animals (Fig. 1, A and B), indicating that 
lipoxins can alter pain processing. These results were also 
processed for calculation of the hyperalgesic index (HI), and 
i.v. LXA4, ATLa, and LXB4 signifi  cantly reduced the HI for 
the 0–4-h time span (Fig. 1 C). Assessment of paw volume by 
measuring paw height with calipers applied across the highest 
point of the dorsum and plantar aspects of the paw revealed a 
reduction in carrageenan-evoked paw edema (Fig. 1 D), sug-
gesting a local antiinfl  ammatory action of lipoxins when this 
delivery route is used.
Peripheral infl  ammation triggers release of factors such as 
PGs not only at the site of infl  ammation but also in the spinal 
cord (9). It is important to note that PGs not only have pro-
infl   ammatory actions but can also drive the initiation of 
the resolution phase via PGE2 and PGD2 actions on PMN 
that include the induction of lipoxygenases that enable 
the formation of lipoxins (10). This led us to investigate 
whether spinal (intrathecal [i.t.])-administrated lipoxins have 
an antihyperalgesic eff  ect. Peripheral aff  erents innervating the 
lower hind limbs, including the paws, terminate at the   lumbar 
level of the spinal cord. To enable local delivery of lipoxins, 
injection catheters were implanted so that the tip of the 
  catheter was placed at the level of the lumbar spinal cord. 
  Although i.t. injection of the vehicle (saline) had no eff  ect on 
carrageenan-induced hyperalgesia, i.t. LXA4 (0.3 nmol) at-
tenuated the carrageenan-evoked hyperalgesia in a dose-
  dependent fashion (Fig. 2, A and C), and equimolar dosing of 
ATLa had a similar eff  ect (Fig. 2 C). On the contrary, i.t. 
LXA4 did not alter normal nociceptive thresholds, as indi-
cated by the lack of change in withdrawal latency of the con-
tralateral (uninfl  amed) paw (Fig. 2 A). Intrathecal injection 
of the positional isomer LXB4 (0.3 nmol) also caused anti-
hyperalgesia, whereas a higher dose of 8,9-aLXB4 (10 nmol) 
was required for similar eff  ects (Fig. 2, B and C). None of 
the  lipoxins altered carrageenan-induced paw edema (Fig. 
2 D). The therapeutic potential of lipoxins was tested by i.t. 
injection of LXA4 at time points when the carrageenan-
  induced hyperalgesia was established. Although a single dose 
of LXA4 (0.3 nmol) showed a modest eff  ect, two consecutive 
injections resulted in a statistically signifi  cant reversal of the 
hyperalgesia (Fig. 2, E and F). To examine whether the anti-
hyperalgesic eff  ect of i.t.-delivered lipoxins is caused by re-
distribution, the same dose of LXA4 that was eff  ective when 
injected i.t. was administered i.v. Intravenous administration 
of 0.3 nmol LXA4 did not reduce carrageenan-evoked thermal 
hyperalgesia or peripheral infl  ammation (Fig. 1 A), and it 
is thus unlikely that the eff  ect observed with spinal adminis-
tration of lipoxins is the result of redistribution from the 
  spinal compartment to the site of infl  ammation. Because 
the trihydroxytetraene structure of native lipoxins is sensitive 
to metabolic inactivation by dehydrogenation, LXA4 was 
  administered via continuous i.t. infusion that resulted in a 
prolonged antihyperalgesic eff  ect compared with i.t. bolus 
injection (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20061826/DC1). These results suggest that 
lipoxins have antinociceptive action not only after systemic 
delivery but also when delivered spinally, and that the 
antihyperalgesic  eff  ect exerted at the spinal level is mediated 
via a mechanism that is distinct from regulation of peripheral 
infl  ammation and edema.
Lipoxins act on ALXR in peripheral tissues, and this re-
ceptor has been cloned from both immune and nonimmune 
cell types, including PMNs, monocytes, T cells, intestinal 
enterocytes, and synovial fi  broblasts (for review see reference 2). 
The antihyperalgesic action observed after i.t. adminis-
tration of LXA4, LXB4, and ATLa indicates that this class of 
lipid mediators also acts on specifi  c targets in the spinal cord. 
Accordingly, we examined whether the lipoxin receptor is 
expressed at the spinal cord of naive rodents. At this point in 
time there is no commercially available antibody against the 
rat ALXR. Based on the fact that rat ALXR shares 74 and 
84% homology with human and mouse ALXR, respectively, 
the immunoreactivity of an antibody against human ALXR 
was examined in rodent tissues. Rat and mouse spinal cord 
homogenates were subjected to gel electrophoresis and West-
ern blotting. ALXR immunoreactive bands, running at 70 kD 
(Fig. 3 A), were detected on membranes probed with this 
antibody, indicating that it recognizes rat, as well as human 
and mouse, ALXR and that the ALXR is constitutively 
  expressed in naive rat and mouse spinal cords (Fig. 3 A).
ALXR expression in intestinal enterocytes increases in 
response to cytokine (IL-13 and IFN-γ) and LPS stimulation 
in vitro (for review see reference 2). To assess whether in-
fl  ammation in peripheral tissues and persistent aff  erent input 
alter the expression of spinal ALXR, spinal cords were col-
lected at diff  erent time points after intraplantar injection of 
carrageenan. Lumbar spinal cords harvested from rats 6, 12, 
and 24 h after injection of carrageenan showed protein ex-
pression levels of ALXR very similar to those observed in 
naive animals (6 h, 115 ± 8%; 12 h, 125 ± 11%; and 24 h, 
119 ± 13% as compared with naive animals; n = 3–5 per 
group; Fig. 3 A). These results emphasize that the spinal ex-
pression of this receptor does not change in the face of pe-
ripheral infl  ammation. To understand the interplay between 
lipoxins, ALXR, and spinal pain processing, it is important to 
determine in which spinal cell type ALXR is expressed. To 
address this question, lumbar spinal cords from naive rats 
were sectioned and incubated with ALXR antibody. ALXR 
immunoreactivity was observed in stellate-like cells through-
out the spinal cord, homogenously distributed in the dorsal 
(Fig. 3 B) and ventral horns (not depicted). Double labeling 248  LIPOXINS AND PAIN | Svensson et al. 
of spinal cord sections revealed that ALXR expression 
  colocalized with the astrocyte marker glial fi  brillary acidic 
protein (GFAP; Fig. 3, C–F) but not with the microglia 
marker OX-42 or the neuronal marker NeuN (Fig. 3, K and L). 
In line with our present results, earlier in vitro studies 
  demonstrated ALXR (FPRL1) expression in astrocytoma 
cells (11). As a positive control, a rat spleen (8 h after paw 
carrageenan injection) was probed for ALXR, and positive 
Figure 2.  Intrathecal injection of lipoxins reduces infl  ammation-
evoked hyperalgesia. Paw withdrawal latency (PWL) is plotted versus 
time for the left ipsilateral (ip) and contralateral (c) hind paw, showing 
that i.t. pretreatment (−2 min) with equimolar doses of LXA4 (A and C), 
LXB4, and ATLa and a higher dose of 8,9-aLXB4 (B and C), as well as post-
treatment with LXA4 (injection at 120 min or at 120 min followed by a 
second injection at 190 min; E and F), reduces infl  ammation-evoked 
  hyperalgesia. HI is calculated for 0–4 h (C) and 2–6 h (F). None of the 
i.t.-delivered lipoxins altered paw thickness (D). Each time point and bar 
represents the mean ± SEM (n = 6–8). *, P < 0.05 as compared with 
vehicle (ip) measurements.JEM VOL. 204, February 19, 2007  249
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cells were observed with both fl  uorescence (Fig. 3 G) and 
avidin-biotin detection (Fig. 3 H). The ALXR immuno-
reactivity was abolished in the goat-serum control (Fig. 3 I). 
ALXR expression was not detected in dorsal root ganglia 
(Fig. 3 J).
The fi  nding that spinal astrocytes express ALXR is in-
triguing, as the number of reports indicating that spinal non-
neuronal cells play an important role in spinal facilitation of 
pain processing is rapidly increasing. It has been shown that 
both nerve injury and peripheral infl  ammation lead to activa-
tion of spinal dorsal horn astrocytes and microglia (12). Spinal 
delivery of inhibitors or modulators of astrocyte function 
block initiation and maintenance of persistent pain states (13–16), 
supporting an important role for these cells in spinal sensitiza-
tion. Astrocytes respond to changes in their environment by 
releasing, for example, cytokines, chemokines, and nitric 
  oxide. Thus, it is possible that lipoxins, by acting on astrocyte 
ALXR, dampen this response by counterregulating the pro-
duction of proinfl  ammatory factors. Based on reports dem-
onstrating that ERK and c-Jun N-terminal kinase (JNK) 
mitogen-activated protein kinase (MAPK) are activated 
(phosphorylated) in spinal astrocytes in models of persistent 
pain (14, 17), we sought to examine the eff  ect of lipoxins on 
ERK and JNK phosphorylation in astrocytes. For this pur-
pose, primary cultures of astrocytes (>95% astrocytes) were 
established from postnatal rat spinal cord, and ALXR expres-
sion was verifi  ed (Fig. 4 A). The astrocyte cultures were sub-
jected to 250 μM of stable ATP, 50 ng/ml TNF-α, 10 ng/ml 
IL-1β, and 10 μM substance P (SP), factors indicated to act 
on glia and play a role in spinal pain processing, for 15 min. 
This study showed that ATP drives activation of both ERK 
and JNK, whereas TNF-α stimulation activated only JNK. 
SP and IL-1β did not evoke phosphorylation of these MAPKs 
at the chosen concentration and time point. Strikingly, ATP-
evoked ERK and JNK phosphorylation, but not TNF-α–
evoked JNK phosphorylation, was reduced in the presence of 
10 nM ATLa (30-min pretreatment). This observation is in 
line with studies in fi  broblasts and T cells where it has been 
shown that ERK activation is attenuated in the presence of 
lipoxins (for review see reference 2). Of importance, ERK 
activity in spinal astrocytes is thought to be important for the 
maintenance of chronic pain, and inhibition of spinal ERK, 
at the time point when it is activated in astrocytes, attenuates 
neuropathic pain (17). In addition to ERK, this work has 
identifi   ed the JNK family as an intracellular mechanism 
through which lipoxins may exert their antiinfl  ammatory and 
antihyperalgesic actions in spinal tissues. Importantly, it has 
been reported that persistent activation of JNK in spinal as-
trocytes appears critical for the maintenance of neuropathic 
pain (14). In the current study, increased JNK activation was 
observed in spinal astrocytes after peripheral infl  ammation, 
Figure 3.  ALXR is expressed on astrocytes in the naive rat 
spinal cord. (A) Representative Western blots depicting ALXR expres-
sion in mouse and rat spinal cords 0–24 h after injection of carra-
geenan to the paw. Rat spleen (from rats 8 h after carrageenan 
injection) was used as positive control. Immunohistological processing 
of spinal cord sections from the naive rat show that ALXR is homo-
genously expressed throughout the dorsal horn of the spinal cord (B), 
colocalizing with the astrocyte marker GFAP (C–E, green; F, enlarged 
image) but not with the microglia marker OX-42 (K, green) or the neu-
ronal marker NeuN (L, green). ALXR immunoreactivity was detected 
with both fl  uorescence (G) and avidin–biotin–3,3-diaminobenzidine (H) 
detection in spleens from carrageenan-injected rats (F). ALXR anti-
body replaced with goat serum IgG was used as a negative control (I). 
ALXR immunoreactivity was absent in dorsal root ganglia (DRG; J). 
Bars, 50 μm.250  LIPOXINS AND PAIN | Svensson et al. 
and the carrageenan-evoked JNK phosphorylation was 
  reduced in the presence of i.t. LXA4 (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20061826/DC1). 
The antihyperalgesic eff  ects observed after i.t. injection of 
  lipoxins in our model of infl  ammatory pain, in conjunction 
with the prevention of JNK activation in vivo and JNK and 
ERK phosphorylation in primary astrocytes, suggest that 
ALXR activation mediates antinociception through preven-
tion of intracellular MAPK signaling in spinal astrocytes. This 
is a striking fi  nding, as it provides support for the existence 
of a mechanism through which spinal nonneuronal cells can 
participate in the regulation of sensory neuronal activity, not 
only through sensitization, but also by normalization, of 
pain signaling.
Earlier results also suggested that lipoxins play an impor-
tant role in pain processing by regulating the communication 
between the immune and sensory nervous system. The neu-
ropeptide nociceptin (orphanin FQ) elicits leukocyte recruit-
ment in vitro and in vivo (18). It is hypothesized that 
nociceptin, released from aff  erent nerve terminals, leads to the 
recruitment of infl  ammatory cells that contribute to the fa-
cilitation of pain processing. Along these lines, i.v. injection of 
ATLa blocked nociceptin-evoked PMN infi  ltration and may 
thereby reduce infl  ammation-evoked pain (18). In the present 
study, systemic administration of lipoxins reduced signs of in-
fl  ammation (i.e., hyperalgesia and edema); even though not 
examined here, it is reasonable to consider that this is medi-
ated in part by lipoxin reduction in PMN infi  ltration. Lipox-
ins also act on monocytes and macrophages, stimulating these 
cells to facilitate resolution of infl   ammation by increased 
monocyte infi  ltration and phagocytosis of apoptotic PMNs in 
a nonphlogistic fashion. It is likely that lipoxins can also at-
tenuate sensitization and activation of sensory neurons through 
their antiinfl  ammatory and proresolving properties, limiting 
the local release of infl  ammatory, pronociceptive factors.
A considerable amount of eff   ort has been focused on 
blocking signals that drive chronic pain either by reducing the 
generation of a single factor (e.g., PGE2 or NO) or by block-
ing factors from acting on their specifi  c receptors (e.g., SP, 
glutamate, or TNF-α). Although these strategies have proven 
to reduce nociception, it is becoming increasingly appreciated 
that targeting systems that aff  ect a broad spectrum of factors 
involved in pain processing may be more advantageous. The 
present results suggest that using agonists that activate path-
ways for antiinfl  ammatory proresolving actions is an eff  ective 
approach for regulation of nociceptive signaling in, but not 
limited to, painful infl  ammatory conditions. Of interest, re-
duced levels of the antiinfl  ammatory cytokines IL-4 and IL-10 
was recently reported in patients with chronic pain (19), 
and IL-4 induces both ALXR and the enzymes in LX bio-
synthesis (for review see reference 2). In accordance, studies 
showing that systemic as well as spinal delivery of IL-4 and 
IL-10, as a protein or through gene transfer, reduces hyper-
sensitivity in experimental models of pain (20, 21) support 
the importance of a counterregulatory system in the control 
of pain signaling. Though not examined in this study, it is pos-
sible that there is an elevation of lipoxins in the spinal cord 
during normal resolution of pain and, conversely, that a re-
duced capacity to produce peripheral and/or spinal lipoxins 
may lead to persistent pain.
In summary, our fi  ndings suggest that lipoxins attenuate 
nociception not only at the site of infl  ammation but also by 
participating in the regulation of spinal pain processing through 
actions on astrocyte-expressed lipoxin receptors. To date, aside 
from the initial studies noted here, the role of lipoxins in pain 
regulation has not been investigated. Accordingly, these results 
provide insights into a novel lipid cascade regulating periph-
eral and spinal sensitization and hyperalgesia and promise to 
shed light onto the role of nonneuronal cells in spinal noci-
ceptive processing. Moreover, they point to novel therapeutic 
targets for antihyperalgesic agents in chronic pain states.
MATERIALS AND METHODS
Animals. All experiments were performed according to protocols approved 
by the Institutional Animal Care Committee of the University of California, 
Figure 4.  ATLa prevents ATP-evoked ERK and JNK phosphorylation 
in primary astrocyte cultures. (A) Representative images demonstrating 
that ALXR colocalizes with the astrocyte marker GFAP in cultured primary 
astrocytes. Bar, 50 μm. (B) Western blots probed for phosphorylated ERK 
and JNK in samples from primary astrocytes stimulated with ATP, SP, 
IL-1β, and TNF-α for 15 min. Incubation with 10 nM ATLa, starting 
30 min before TNF-α stimulation, had no effect on JNK phosphorylation (C), 
whereas ATLa prevented both ERK and JNK phosphorylation evoked by 
ATP (D and E). Each bar represents the mean ± SEM (n = 4–5). *, P < 0.05 
as compared with control; #, P < 0.05 as compared with PBS + ATP.JEM VOL. 204, February 19, 2007  251
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San Diego. 250–300 g male Sprague Dawley rats (Harlan Industries) were 
housed individually on a 12-h light/dark cycle with free access to food and 
water. Intrathecal injection catheters were implanted through an incision in 
the atlanto-occipital membrane and advanced to the lumbar level under 
  isofl  urane anesthesia. All agents were delivered in 10 μl saline followed by 
10-μl saline fl  ush. For continuous infusion, the catheter was attached to 
an s.c. osmotic minipump (ALZET). For these studies, synthetic LXA4, 
LXB4, and 8,9-LXB4 were purchased from D. Clissold (CASCADE Limited), 
and ATLa was a gift from W. Gilford, J. Parkinson, and H.D. Perez at 
Berlex Biosciences.
Astrocyte cultures. Astrocyte cultures were prepared from spinal cords of 
1–2-d-old rat pups and plated in DMEM containing 10% FBS and 1% 
  penicillin/streptomycin in 75-cm2 fl  asks. At days 13 and 14, the fl  asks were 
mechanically shaken for 2 h to remove any remaining oligodendrocytes and 
microglia. On day 15, the astrocyte cultures were trypsinized and replated into 
six-well dishes. The cells were used for stimulation experiments with SP, 
TNF-α, Bz-ATP (Sigma-Aldrich), and IL-1β (R&D Systems) when confl  uent.
Carrageenan-induced hyperalgesia. 100 μl carrageenan 2% in saline 
(λ; Sigma-Aldrich) was injected s.c. into the plantar surface of the left hind paw 
under light isofl  urane anesthesia. The rats were placed in plexiglass cubicles 
on a glass surface maintained at 25°C for assessment of thermal hyperalgesia (8). 
A thermal nociceptive stimulus was generated by a projection light bulb 
  positioned below the glass surface. Paw withdrawal latency was defi  ned as 
the time until the rat showed a brisk withdrawal response to the heat gener-
ated by the light projected to the paw. The time was determined by a timer 
activated by the light source and stopped by photodiode motion sensors. 
The HI represents the area beneath the time-course curve after stimulation 
in which the percent reduction from baseline latency is plotted against time 
such that the numeric value increases with increased hyperalgesia. The re-
sulting calculated number is the percent change × hours. The formula for 
calculating the percent change is (baseline latency − postdrug latency) × 
100(baseline latency)−1, where latency is expressed in seconds.
Western blotting. The lumbar part of the spinal cord and cultured astro-
cytes were homogenized and subjected to PAGE. Membranes were incu-
bated with antibodies against ALXR (1:2,000; Biologicals), phosphorylated 
JNK (P-JNK), total JNK, phosphorylated (P-ERK), and total ERK 
(1:10,000; Cell Signaling). The signal was detected with chemiluminescent 
reagents (SuperSignal; Pierce Chemical Co.). The membranes were reblot-
ted with GAPDH or β-actin (1:50,000; Sigma-Aldrich). The intensity of 
immunoreactive bands was quantifi  ed using ImageQuant software (Molecular 
Dynamics), pooled for P-ERK and P-JNK, respectively, normalized against 
β-actin, and presented as the percentage of control.
Immunohistochemistry. Animals were perfused with saline followed by 
4% paraformaldehyde. Spinal lumbar enlargement was removed, postfi  xed, 
and cryoprotected. Nonspecifi  c binding was blocked, and cultured astro-
cytes and spinal fl  oating sections (30 μm) were incubated with ALXR 
  antibody (1:500) overnight at 4°C. Alexa Fluor–conjugated secondary 
  antibodies (Invitrogen) were used for detection. The slides were double 
stained with GFAP (1:1,000; Chemicon). Images were captured using a 
multiphoton   laser point scanning confocal microscopy system (Radiance 
2100/AGR-3Q; Bio-Rad Laboratories) operated by Lasersharp 2000 software 
(Bio-Rad Laboratories).
Statistics. One-way analysis of variance was performed to analyze HI, paw 
thickness, and densitometric calculations from Western blot studies. Multi-
ple post hoc comparisons used the Bonferroni correction. P < 0.05 was 
considered signifi  cant.
Online supplemental material. Fig. S1 shows that continuous i.t. infu-
sion of LXA4 resulted in a prolonged antihyperalgesic eff  ect compared with 
i.t. bolus injection of LXA4. Intrathecal catheters were implanted and con-
nected to osmotic minipumps (pump rate = 1 μl/h) prefi  lled with 0.01–0.1 
μg/μl LXA4 solution (0.03–0.3 nmol/h). The pumps and i.t catheters were 
implanted and connected 36 h before the carrageenan injection. It takes 
10–14 h before the infusate reaches the spinal fl  uid; hence, this administration 
regimen provide a 20–24 h lipoxin pretreatment. Hyperalgesia was assessed 
by measuring time to response to thermal stimuli. Paw volume was assessed 
by paw height measured with calipers applied across the highest point of the 
dorsum and plantar aspects of the paw.
Fig. S2 demonstrates that phosphorylation of spinal JNK, evoked by 
peripheral infl  ammation, was reduced in the presence of i.t. LXA4. Rats re-
ceived i.t. injections of vehicle (saline) or 0.3 nmol LXA4 2 min before and 
120 min after carrageenan injection to the paw. The dorsal ipsilateral lumbar 
enlargement of spinal cords was harvested 4 h after injection of carrageenan, 
homogenized, and subjected to PAGE. Membranes were incubated with 
antibodies against P-JNK, total JNK (1:10,000; Cell Signaling), and β-actin 
(1:50,000; Sigma-Aldrich). The signal was detected with chemiluminescent 
reagents. Intensity of immunoreactive bands were quantifi  ed using Image-
Quant software. The signal for P-JNK bands was pooled, normalized 
against total JNK, and presented as the percentage of control.
For immunohistochemistry, animals were perfused with saline followed 
by 4% paraformaldehyde. Spinal lumbar enlargement was removed, post-
fi  xed, and cryoprotected. Nonspecifi  c binding was blocked, and the 30-μm 
fl  oating sections were incubated with monoclonal P-JNK antibody (1:100; 
Cell Signaling) overnight at room temperature. Alexa Fluor–conjugated sec-
ondary antibodies (Invitrogen) were used for detection. The slides were 
double stained with polyclonal GFAP antibody (1:500; Chemicon). Images 
were captured using a confocal microscopy system operated by Lasersharp 
2000 software.
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